Not provided
Not provided
Not provided
Not provided
Not provided
Sponsor's decision to change the clinical development plan of this molecule. This decision is not based on efficacy or safety concerns.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical study is to learn more about the impact of cobicistat (COBI) (P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and strong cytochrome P450 enzyme [CYP]3A inhibitor), voriconazole (VOR) (strong CYP3A inhibitor), and rifabutin (RFB) (moderate CYP3A inducer) on the study drug, vesatolimod (VES), in people with HIV-1 on antiretroviral therapy (ART).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort 1: Vesatolimod + Cobicistat + Voriconazole | Experimental | Participants will receive a single dose of vesatolimod (VES) 2 mg on Day 1 of Period 1. In Period 2, participants will receive cobicistat (COBI) 150 mg once daily on Days 1 to 5 along with a single dose of VES 2 mg on Day 2. In Period 3, participants will receive a loading dose of voriconazole (VOR) 400 mg twice daily on Day 1, then VOR 200 mg twice daily on Days 2 to 6, and a single dose of VES 2 mg in the morning on Day 3. There will be a washout period of 7 to 14 days between treatments in Period 1 Day 1 and Period 2 Day 1 and a washout period of 14 to 21 days between treatments in Period 2 Day 5 and Period 3 Day 1. |
|
| Cohort 2: Vesatolimod + Rifabutin | Experimental | Participants will receive a single dose of VES 6 mg on Day 1. In Period 2, participants will receive Rifabutin (RFB) 300 mg once daily on Days 1 to 9 along with a single dose of VES 6 mg on Day 6. There will be a washout period of 7 to 14 days between treatments in Period 1 Day 1 and Period 2 Day 1. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vesatolimod | Drug | Administered orally |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacokinetic (PK) Parameter : AUClast of Vesatolimod (VES) | AUClast is defined as an area under the concentration versus time curve from time zero to the last quantifiable concentration. Cohort 1 Period 1 Day 1: Day 1 from Baseline; Cohort 1 Period 2 Day 2: Up to Day 17 from Baseline; Cohort 1 Period 3 Day 3: Up to Day 44 from Baseline; Cohort 2 Period 1 Day 1: Day 1 from Baseline; Cohort 2 Period 2 Day 6: Up to Day 21 from Baseline. | Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose for Cohort 1 on Period 1 Day 1, Period 2 Day 2, and Period 3 Day 3; and for Cohort 2 on Period 1 Day 1 and Period 2 Day 6 |
| PK Parameter : AUCinf of VES | AUCinf is defined as an area under the concentration versus time curve extrapolated to infinite time, calculated as AUClast + (Clast/Lambda z). Cohort 1 Period 1 Day 1: Day 1 from Baseline; Cohort 1 Period 2 Day 2: Up to Day 17 from Baseline; Cohort 1 Period 3 Day 3: Up to Day 44 from Baseline; Cohort 2 Period 1 Day 1: Day 1 from Baseline; Cohort 2 Period 2 Day 6: Up to Day 21 from Baseline. | Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose for Cohort 1 on Period 1 Day 1, Period 2 Day 2, and Period 3 Day 3; and for Cohort 2 on Period 1 Day 1 and Period 2 Day 6 |
| PK Parameter : Cmax of VES | Cmax is defined as the maximum observed concentration of drug. Cohort 1 Period 1 Day 1: Day 1 from Baseline; Cohort 1 Period 2 Day 2: Up to Day 17 from Baseline; Cohort 1 Period 3 Day 3: Up to Day 44 from Baseline; Cohort 2 Period 1 Day 1: Day 1 from Baseline; Cohort 2 Period 2 Day 6: Up to Day 21 from Baseline. | Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose for Cohort 1 on Period 1 Day 1, Period 2 Day 2, and Period 3 Day 3; and for Cohort 2 on Period 1 Day 1 and Period 2 Day 6 |
| PK Parameter : %AUCexp of VES | %AUCexp is defined as the percentage of AUC extrapolated between AUClast and AUCinf, calculated as ([AUCinf-AUClast]/AUCinf)*100. Cohort 1 Period 1 Day 1: Day 1 from Baseline; Cohort 1 Period 2 Day 2: Up to Day 17 from Baseline; Cohort 1 Period 3 Day 3: Up to Day 44 from Baseline; Cohort 2 Period 1 Day 1: Day 1 from Baseline; Cohort 2 Period 2 Day 6: Up to Day 21 from Baseline. |
Not provided
Not provided
Key Inclusion Criteria:
On an antiretroviral therapy (ART) regimen for at least 6 consecutive months, with no change in the ART regimen within 2 months prior to screening. Permitted ARTs are as follows:
Plasma HIV-1 RNA levels less than 50 copies/mL at screening
Have normal hematologic function with an absolute neutrophil count greater than or equal to 1.5 × 10^9/L, platelets greater than or equal to 150 × 10^9/L; hemoglobin greater than or equal to 10.5 g/dL for females and greater than or equal to 11.5 g/dL for males
Clusters of differentiation (CD) 4 T cell count greater than or equal to 350 cells/μL
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 2.5 x upper limit of normal (ULN) and total bilirubin less than or equal to 1.5 mg/dL, or normal direct bilirubin and creatinine less than or equal to 1.25 x ULN
Have a calculated creatinine clearance (CLcr) of at least 60 mL/min (using the Cockcroft-Gault method) based on serum creatinine and actual body weight as measured at screening and upon admission
Individuals assigned female at birth and of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception
Must be willing and able to comply with all study requirements and available to complete the study schedule of assessments
In the judgment of the investigator, be in good general health, based on review of the results from a screening visit
Key Exclusion Criteria:
Have received any study drug within 30 days prior to study dosing
Participation in any other clinical study (including observation studies) without prior approval from the sponsor is prohibited while participating in this study
Have current alcohol or substance abuse judged by the investigator to potentially interfere with individual compliance or individual safety, or a positive drug or alcohol test at screening or baseline
No Evidence of chronic hepatitis B virus (HBV) infection (defined as positive hepatitis B surface antigen [HBsAg] and/or positive HBV core antibody with positive reflex HBV DNA polymerase chain reaction (PCR)). Note: positive HBV core antibody with negative reflex HBV DNA PCR results are acceptable
No Evidence of active hepatitis C virus (HCV) infection (defined as positive hepatitis C antibody and HCV RNA above lower limit of quantitation). Note: positive anti-HCV antibody and negative HCV PCR results are acceptable
Acute febrile illness within 35 days prior to Day 1
Have been treated with systemic steroids, immunosuppressant therapies, or chemotherapeutic agents within 3 months prior to screening or is expected to receive these agents during the study
Received any vaccine or immunomodulatory medication within 4 weeks prior to screening. Elective vaccination (eg, flu shot, hepatitis A or B vaccine) during the course of the study will require prior approval from the sponsor
Have a history of any of the following:
Have any serious or active medical or psychiatric illness (including depression) that, in the opinion of the investigator, would interfere with individual treatment, assessment, or compliance with the protocol
For Cohort 1, individuals with CYP2C19 genotype of CYP2C19*2/*2, CYP2C19*2/*3, or CYP2C19*3/*3
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gilead Study Director | Gilead Sciences | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Collaborative Neuroscience Research, LLC. | Long Beach | California | 90806 | United States | ||
| Clinical Pharmacology of Miami, LLC. |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40952649 | Derived | Zheng Y, Wire M, Omange RW, deVries CR, Zhang L, Chen B, Huang SSY, Cruz K, Hassman H, Osiyemi O, Rondon JC, Lim D, West S, Wen A, Wallin JJ, SenGupta D, Cai Y. The Effects of Cobicistat and Voriconazole on the Safety, Pharmacokinetics, and Pharmacodynamics of the TLR7 Agonist Vesatolimod in People with HIV. Infect Dis Ther. 2025 Nov;14(11):2535-2549. doi: 10.1007/s40121-025-01227-x. Epub 2025 Sep 15. |
| Label | URL |
|---|---|
| Gilead Clinical Trials Website | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
59 participants were screened.
Participants were enrolled at study sites in the United States.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Cohort 1: Vesatolimod + Cobicistat + Voriconazole | Participants received a single dose of vesatolimod (VES) 2 mg on Day 1 of Period 1. In Period 2, participants received cobicistat (COBI) 150 mg once daily on Days 1 to 5 along with a single dose of VES 2 mg on Day 2. In Period 3, participants received a loading dose of voriconazole (VOR) 400 mg twice daily on Day 1, then VOR 200 mg twice daily on Days 2 to 6, and a single dose of VES 2 mg in the morning on Day 3. There was a washout period of 7 to 14 days between treatments in Period 1 Day 1 and Period 2 Day 1 and a washout period of 14 to 21 days between treatments in Period 2 Day 5 and Period 3 Day 1. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Dec 12, 2022 | Apr 5, 2024 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Cobicistat | Drug | Administered orally |
|
|
| Voriconazole | Drug | Administered orally |
|
|
| Rifabutin | Drug | Administered orally |
|
|
| Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose for Cohort 1 on Period 1 Day 1, Period 2 Day 2, and Period 3 Day 3; and for Cohort 2 on Period 1 Day 1 and Period 2 Day 6 |
| PK Parameter : Tmax of VES | Tmax is defined as the time (observed time point) of Cmax. Cohort 1 Period 1 Day 1: Day 1 from Baseline; Cohort 1 Period 2 Day 2: Up to Day 17 from Baseline; Cohort 1 Period 3 Day 3: Up to Day 44 from Baseline; Cohort 2 Period 1 Day 1: Day 1 from Baseline; Cohort 2 Period 2 Day 6: Up to Day 21 from Baseline. | Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose for Cohort 1 on Period 1 Day 1, Period 2 Day 2, and Period 3 Day 3; and for Cohort 2 on Period 1 Day 1 and Period 2 Day 6 |
| PK Parameter : Clast of VES | Clast is defined as the last observed quantifiable concentration of the drug. Cohort 1 Period 1 Day 1: Day 1 from Baseline; Cohort 1 Period 2 Day 2: Up to Day 17 from Baseline; Cohort 1 Period 3 Day 3: Up to Day 44 from Baseline; Cohort 2 Period 1 Day 1: Day 1 from Baseline; Cohort 2 Period 2 Day 6: Up to Day 21 from Baseline. | Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose for Cohort 1 on Period 1 Day 1, Period 2 Day 2, and Period 3 Day 3; and for Cohort 2 on Period 1 Day 1 and Period 2 Day 6 |
| PK Parameter : Tlast of VES | Tlast is defined as the time (observed time point) of Clast. Cohort 1 Period 1 Day 1: Day 1 from Baseline; Cohort 1 Period 2 Day 2: Up to Day 17 from Baseline; Cohort 1 Period 3 Day 3: Up to Day 44 from Baseline; Cohort 2 Period 1 Day 1: Day 1 from Baseline; Cohort 2 Period 2 Day 6: Up to Day 21 from Baseline. | Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose for Cohort 1 on Period 1 Day 1, Period 2 Day 2, and Period 3 Day 3; and for Cohort 2 on Period 1 Day 1 and Period 2 Day 6 |
| PK Parameter : Lambda z of VES | Lambda z is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log concentration of drug versus time curve of the drug. Cohort 1 Period 1 Day 1: Day 1 from Baseline; Cohort 1 Period 2 Day 2: Up to Day 17 from Baseline; Cohort 1 Period 3 Day 3: Up to Day 44 from Baseline; Cohort 2 Period 1 Day 1: Day 1 from Baseline; Cohort 2 Period 2 Day 6: Up to Day 21 from Baseline. | Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose for Cohort 1 on Period 1 Day 1, Period 2 Day 2, and Period 3 Day 3; and for Cohort 2 on Period 1 Day 1 and Period 2 Day 6 |
| PK Parameter : t1/2 of VES | t1/2 is defined as the terminal elimination half-life. Cohort 1 Period 1 Day 1: Day 1 from Baseline; Cohort 1 Period 2 Day 2: Up to Day 17 from Baseline; Cohort 1 Period 3 Day 3: Up to Day 44 from Baseline; Cohort 2 Period 1 Day 1: Day 1 from Baseline; Cohort 2 Period 2 Day 6: Up to Day 21 from Baseline. | Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose for Cohort 1 on Period 1 Day 1, Period 2 Day 2, and Period 3 Day 3; and for Cohort 2 on Period 1 Day 1 and Period 2 Day 6 |
| PK Parameter : CL/F of VES | CL/F is defined as an apparent oral clearance. Cohort 1 Period 1 Day 1: Day 1 from Baseline; Cohort 1 Period 2 Day 2: Up to Day 17 from Baseline; Cohort 1 Period 3 Day 3: Up to Day 44 from Baseline; Cohort 2 Period 1 Day 1: Day 1 from Baseline; Cohort 2 Period 2 Day 6: Up to Day 21 from Baseline. | Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose for Cohort 1 on Period 1 Day 1, Period 2 Day 2, and Period 3 Day 3; and for Cohort 2 on Period 1 Day 1 and Period 2 Day 6 |
| PK Parameter : Vz/F of VES | Vz/F is defined as an apparent volume of distribution of the drug. Cohort 1 Period 1 Day 1: Day 1 from Baseline; Cohort 1 Period 2 Day 2: Up to Day 17 from Baseline; Cohort 1 Period 3 Day 3: Up to Day 44 from Baseline; Cohort 2 Period 1 Day 1: Day 1 from Baseline; Cohort 2 Period 2 Day 6: Up to Day 21 from Baseline. | Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose for Cohort 1 on Period 1 Day 1, Period 2 Day 2, and Period 3 Day 3; and for Cohort 2 on Period 1 Day 1 and Period 2 Day 6 |
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) | An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a study drug that does not necessarily have a causal relationship with the treatment. An AE can, therefore, be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the study drug. Adverse events may also include pretreatment or posttreatment complications that occur as a result of protocol-specified procedures, or special situations. TEAES included all AEs began on or after the study drug start date. | First dose date up to last dose date plus 30 days (up to 77 days for Cohort 1, and up to 54 days for Cohort 2) |
| Percentage of Participants Who Experienced Treatment-Emergent Laboratory Abnormalities | A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from predose at any time postdose. Data for participants with post baseline toxicity grade 1 or higher is reported. | First dose date up to last dose date plus 30 days (up to 77 days for Cohort 1, and up to 54 days for Cohort 2) |
| Miami |
| Florida |
| 33014 |
| United States |
| Advanced Pharma, CR, LLC. | Miami | Florida | 33147 | United States |
| Triple O Research Institute, P.A. | West Palm Beach | Florida | 33407 | United States |
| Hassman Research Institute | Marlton | New Jersey | 08054 | United States |
| FG001 | Cohort 2: Vesatolimod + Rifabutin | Participants received a single dose of VES 6 mg on Day 1. In Period 2, participants received Rifabutin (RFB) 300 mg once daily on Days 1 to 9 along with a single dose of VES 6 mg on Day 6. There was a washout period of 7 to 14 days between treatments in Period 1 Day 1 and Period 2 Day 1. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
The Safety Analysis Set included all enrolled participants who received at least 1 dose of study drug.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Cohort 1: Vesatolimod + Cobicistat + Voriconazole | Participants received a single dose of vesatolimod (VES) 2 mg on Day 1 of Period 1. In Period 2, participants received cobicistat (COBI) 150 mg once daily on Days 1 to 5 along with a single dose of VES 2 mg on Day 2. In Period 3, participants received a loading dose of voriconazole (VOR) 400 mg twice daily on Day 1, then VOR 200 mg twice daily on Days 2 to 6, and a single dose of VES 2 mg in the morning on Day 3. There was a washout period of 7 to 14 days between treatments in Period 1 Day 1 and Period 2 Day 1 and a washout period of 14 to 21 days between treatments in Period 2 Day 5 and Period 3 Day 1. |
| BG001 | Cohort 2: Vesatolimod + Rifabutin | Participants received a single dose of VES 6 mg on Day 1. In Period 2, participants received Rifabutin (RFB) 300 mg once daily on Days 1 to 9 along with a single dose of VES 6 mg on Day 6. There was a washout period of 7 to 14 days between treatments in Period 1 Day 1 and Period 2 Day 1. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants | No |
| |||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Data for Cohort 2 are not reported due to participants' confidentiality reasons as there were only 2 participants in this cohort. | Count of Participants | Participants | No |
| ||||||||||||||
| Ethnicity (NIH/OMB) | Data for Cohort 2 are not reported due to participants' confidentiality reasons as there were only 2 participants in this cohort. | Count of Participants | Participants | No |
| ||||||||||||||
| Race (NIH/OMB) | Data for Cohort 2 are not reported due to participants' confidentiality reasons as there were only 2 participants in this cohort. | Count of Participants | Participants | No |
| ||||||||||||||
| Region of Enrollment | Count of Participants | Participants | No |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Pharmacokinetic (PK) Parameter : AUClast of Vesatolimod (VES) | AUClast is defined as an area under the concentration versus time curve from time zero to the last quantifiable concentration. Cohort 1 Period 1 Day 1: Day 1 from Baseline; Cohort 1 Period 2 Day 2: Up to Day 17 from Baseline; Cohort 1 Period 3 Day 3: Up to Day 44 from Baseline; Cohort 2 Period 1 Day 1: Day 1 from Baseline; Cohort 2 Period 2 Day 6: Up to Day 21 from Baseline. | The VES PK Analysis Set included participants who received at least 1 dose of VES and had at least 1 nonmissing PK concentration value. | Posted | Mean | Standard Deviation | h*pg/mL | Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose for Cohort 1 on Period 1 Day 1, Period 2 Day 2, and Period 3 Day 3; and for Cohort 2 on Period 1 Day 1 and Period 2 Day 6 |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | PK Parameter : AUCinf of VES | AUCinf is defined as an area under the concentration versus time curve extrapolated to infinite time, calculated as AUClast + (Clast/Lambda z). Cohort 1 Period 1 Day 1: Day 1 from Baseline; Cohort 1 Period 2 Day 2: Up to Day 17 from Baseline; Cohort 1 Period 3 Day 3: Up to Day 44 from Baseline; Cohort 2 Period 1 Day 1: Day 1 from Baseline; Cohort 2 Period 2 Day 6: Up to Day 21 from Baseline. | Participants in the VES PK Analysis Set with available data were analyzed. Data for Cohort 2 Vesatolimod 6mg are not reported due to participant's confidentiality reasons as there was only 1 participant in this cohort. | Posted | Mean | Standard Deviation | h*pg/mL | Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose for Cohort 1 on Period 1 Day 1, Period 2 Day 2, and Period 3 Day 3; and for Cohort 2 on Period 1 Day 1 and Period 2 Day 6 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | PK Parameter : Cmax of VES | Cmax is defined as the maximum observed concentration of drug. Cohort 1 Period 1 Day 1: Day 1 from Baseline; Cohort 1 Period 2 Day 2: Up to Day 17 from Baseline; Cohort 1 Period 3 Day 3: Up to Day 44 from Baseline; Cohort 2 Period 1 Day 1: Day 1 from Baseline; Cohort 2 Period 2 Day 6: Up to Day 21 from Baseline. | Participants in the VES PK Analysis Set were analyzed. | Posted | Mean | Standard Deviation | pg/mL | Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose for Cohort 1 on Period 1 Day 1, Period 2 Day 2, and Period 3 Day 3; and for Cohort 2 on Period 1 Day 1 and Period 2 Day 6 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | PK Parameter : %AUCexp of VES | %AUCexp is defined as the percentage of AUC extrapolated between AUClast and AUCinf, calculated as ([AUCinf-AUClast]/AUCinf)*100. Cohort 1 Period 1 Day 1: Day 1 from Baseline; Cohort 1 Period 2 Day 2: Up to Day 17 from Baseline; Cohort 1 Period 3 Day 3: Up to Day 44 from Baseline; Cohort 2 Period 1 Day 1: Day 1 from Baseline; Cohort 2 Period 2 Day 6: Up to Day 21 from Baseline. | Participants in the VES PK Analysis Set with available data were analyzed. Data for Cohort 2 Vesatolimod 6mg are not reported due to participant's confidentiality reasons as there was only 1 participant in this cohort. | Posted | Mean | Standard Deviation | percentage of AUCexp | Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose for Cohort 1 on Period 1 Day 1, Period 2 Day 2, and Period 3 Day 3; and for Cohort 2 on Period 1 Day 1 and Period 2 Day 6 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | PK Parameter : Tmax of VES | Tmax is defined as the time (observed time point) of Cmax. Cohort 1 Period 1 Day 1: Day 1 from Baseline; Cohort 1 Period 2 Day 2: Up to Day 17 from Baseline; Cohort 1 Period 3 Day 3: Up to Day 44 from Baseline; Cohort 2 Period 1 Day 1: Day 1 from Baseline; Cohort 2 Period 2 Day 6: Up to Day 21 from Baseline. | Participants in the VES PK Analysis Set were analyzed. | Posted | Median | Inter-Quartile Range | hours | Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose for Cohort 1 on Period 1 Day 1, Period 2 Day 2, and Period 3 Day 3; and for Cohort 2 on Period 1 Day 1 and Period 2 Day 6 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | PK Parameter : Clast of VES | Clast is defined as the last observed quantifiable concentration of the drug. Cohort 1 Period 1 Day 1: Day 1 from Baseline; Cohort 1 Period 2 Day 2: Up to Day 17 from Baseline; Cohort 1 Period 3 Day 3: Up to Day 44 from Baseline; Cohort 2 Period 1 Day 1: Day 1 from Baseline; Cohort 2 Period 2 Day 6: Up to Day 21 from Baseline. | Participants in the VES PK Analysis Set were analyzed. | Posted | Mean | Standard Deviation | pg/mL | Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose for Cohort 1 on Period 1 Day 1, Period 2 Day 2, and Period 3 Day 3; and for Cohort 2 on Period 1 Day 1 and Period 2 Day 6 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | PK Parameter : Tlast of VES | Tlast is defined as the time (observed time point) of Clast. Cohort 1 Period 1 Day 1: Day 1 from Baseline; Cohort 1 Period 2 Day 2: Up to Day 17 from Baseline; Cohort 1 Period 3 Day 3: Up to Day 44 from Baseline; Cohort 2 Period 1 Day 1: Day 1 from Baseline; Cohort 2 Period 2 Day 6: Up to Day 21 from Baseline. | Participants in the VES PK Analysis Set were analyzed. | Posted | Median | Inter-Quartile Range | hours | Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose for Cohort 1 on Period 1 Day 1, Period 2 Day 2, and Period 3 Day 3; and for Cohort 2 on Period 1 Day 1 and Period 2 Day 6 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | PK Parameter : Lambda z of VES | Lambda z is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log concentration of drug versus time curve of the drug. Cohort 1 Period 1 Day 1: Day 1 from Baseline; Cohort 1 Period 2 Day 2: Up to Day 17 from Baseline; Cohort 1 Period 3 Day 3: Up to Day 44 from Baseline; Cohort 2 Period 1 Day 1: Day 1 from Baseline; Cohort 2 Period 2 Day 6: Up to Day 21 from Baseline. | Participants in the VES PK Analysis Set with available data were analyzed. Data for Cohort 2 Vesatolimod 6mg are not reported due to participant's confidentiality reasons as there was only 1 participant in this cohort. | Posted | Median | Inter-Quartile Range | per hour | Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose for Cohort 1 on Period 1 Day 1, Period 2 Day 2, and Period 3 Day 3; and for Cohort 2 on Period 1 Day 1 and Period 2 Day 6 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | PK Parameter : t1/2 of VES | t1/2 is defined as the terminal elimination half-life. Cohort 1 Period 1 Day 1: Day 1 from Baseline; Cohort 1 Period 2 Day 2: Up to Day 17 from Baseline; Cohort 1 Period 3 Day 3: Up to Day 44 from Baseline; Cohort 2 Period 1 Day 1: Day 1 from Baseline; Cohort 2 Period 2 Day 6: Up to Day 21 from Baseline. | Participants in the VES PK Analysis Set with available data were analyzed. Data for Cohort 2 Vesatolimod 6mg are not reported due to participant's confidentiality reasons as there was only 1 participant in this cohort. | Posted | Median | Inter-Quartile Range | hours | Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose for Cohort 1 on Period 1 Day 1, Period 2 Day 2, and Period 3 Day 3; and for Cohort 2 on Period 1 Day 1 and Period 2 Day 6 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | PK Parameter : CL/F of VES | CL/F is defined as an apparent oral clearance. Cohort 1 Period 1 Day 1: Day 1 from Baseline; Cohort 1 Period 2 Day 2: Up to Day 17 from Baseline; Cohort 1 Period 3 Day 3: Up to Day 44 from Baseline; Cohort 2 Period 1 Day 1: Day 1 from Baseline; Cohort 2 Period 2 Day 6: Up to Day 21 from Baseline. | Participants in the VES PK Analysis Set with available data were analyzed. Data for Cohort 2 Vesatolimod 6mg are not reported due to participant's confidentiality reasons as there was only 1 participant in this cohort. | Posted | Mean | Standard Deviation | L/h | Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose for Cohort 1 on Period 1 Day 1, Period 2 Day 2, and Period 3 Day 3; and for Cohort 2 on Period 1 Day 1 and Period 2 Day 6 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | PK Parameter : Vz/F of VES | Vz/F is defined as an apparent volume of distribution of the drug. Cohort 1 Period 1 Day 1: Day 1 from Baseline; Cohort 1 Period 2 Day 2: Up to Day 17 from Baseline; Cohort 1 Period 3 Day 3: Up to Day 44 from Baseline; Cohort 2 Period 1 Day 1: Day 1 from Baseline; Cohort 2 Period 2 Day 6: Up to Day 21 from Baseline. | Participants in the VES PK Analysis Set with available data were analyzed. Data for Cohort 2 Vesatolimod 6mg are not reported due to participant's confidentiality reasons as there was only 1 participant in this cohort. | Posted | Mean | Standard Deviation | L | Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose for Cohort 1 on Period 1 Day 1, Period 2 Day 2, and Period 3 Day 3; and for Cohort 2 on Period 1 Day 1 and Period 2 Day 6 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) | An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a study drug that does not necessarily have a causal relationship with the treatment. An AE can, therefore, be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the study drug. Adverse events may also include pretreatment or posttreatment complications that occur as a result of protocol-specified procedures, or special situations. TEAES included all AEs began on or after the study drug start date. | Participants in Safety Analysis Set were analyzed. Per planned analysis, the data for adverse events were summarized by study treatments administered in Cohorts 1 and 2 per period. | Posted | Number | percentage of participants | First dose date up to last dose date plus 30 days (up to 77 days for Cohort 1, and up to 54 days for Cohort 2) |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Percentage of Participants Who Experienced Treatment-Emergent Laboratory Abnormalities | A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from predose at any time postdose. Data for participants with post baseline toxicity grade 1 or higher is reported. | Participants in Safety Analysis Set with available data were analyzed. Per planned analysis, the data for adverse events were summarized by study treatments administered in Cohorts 1 and 2 per period. | Posted | Number | percentage of participants | First dose date up to last dose date plus 30 days (up to 77 days for Cohort 1, and up to 54 days for Cohort 2) |
|
Adverse Events and All-cause mortality: Up to 77 days for Cohort 1 and up to 54 days for Cohort 2
All-cause mortality: All Enrolled Analysis Set included all participants who received study participant identification number in study after screening. Cohort 1: No treatment group is reported for 1 participant who was enrolled but never treated.
Adverse Events: Safety Analysis Set included all participants who took at least 1 dose of study drug. Per planned analysis, Adverse Events/All-cause mortality were summarized by study treatments administered in Cohort 1 and Cohort 2 per period.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Cohort 1: Vesatolimod 2 mg | Participants received a single dose of VES 2 mg on Day 1 of Period 1. | 0 | 15 | 0 | 15 | 2 | 15 |
| EG001 | Cohort 1: Cobicistat 150 mg | Participants received COBI 150 mg once daily on Days 1 to 5 in Period 2. | 0 | 13 | 0 | 13 | 5 | 13 |
| EG002 | Cohort 1: Vesatolimod 2 mg + Cobicistat 150 mg | Participants received COBI 150 mg once along with a single dose of VES 2 mg on Day 2 in Period 2. | 0 | 13 | 0 | 13 | 0 | 13 |
| EG003 | Cohort 1: Voriconazole 400 mg | Participants received a loading dose of VOR 400 mg twice daily on Day 1 in Period 3. | 0 | 11 | 0 | 11 | 4 | 11 |
| EG004 | Cohort 1: Voriconazole 200 mg | Participants received VOR 200 mg twice daily on Days 2 to 6 in Period 3. | 0 | 11 | 0 | 11 | 1 | 11 |
| EG005 | Cohort 1: Vesatolimod 2 mg + Voriconazole 200 mg | Participants received VOR 200 mg twice along with a single dose of VES 2 mg on Day 3 in Period 3. | 0 | 11 | 0 | 11 | 1 | 11 |
| EG006 | Cohort 1: No Treatment | Participant was enrolled but was not dosed. | 0 | 1 | 0 | 0 | 0 | 0 |
| EG007 | Cohort 2: Vesatolimod 6 mg | Participants received a single dose of VES 6 mg on Day 1 in Period 1. | 0 | 2 | 0 | 2 | 0 | 2 |
| EG008 | Cohort 2: Rifabutin 300 mg | Participants received RFB 300 mg once daily on Days 1 to 9 in Period 2. | 0 | 2 | 0 | 2 | 1 | 2 |
| EG009 | Cohort 2: Vesatolimod 6 mg + Rifabutin 300 mg | Participants received RFB 300 mg once along with a single dose of VES 6 mg on Day 6 in Period 2. | 0 | 2 | 0 | 2 | 1 | 2 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Photophobia | Eye disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Photopsia | Eye disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Vision blurred | Eye disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Visual impairment | Eye disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Hypersensitivity | Immune system disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Covid-19 | Infections and infestations | MedDRA 26.1 | Systematic Assessment |
| |
| Decreased appetite | Metabolism and nutrition disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Hallucination | Psychiatric disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Proteinuria | Renal and urinary disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Chills | General disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Fatigue | General disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Tachycardia | Cardiac disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Cytokine release syndrome | Immune system disorders | MedDRA 26.1 | Systematic Assessment |
|
After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Gilead Clinical Study Information Center | Gilead Sciences | 1-833-445-3230 (GILEAD-0) | GileadClinicalTrials@gilead.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jan 19, 2024 | Apr 5, 2024 | SAP_001.pdf |
| ID | Term |
|---|---|
| D000163 | Acquired Immunodeficiency Syndrome |
| D007239 | Infections |
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D015229 | Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012897 | Slow Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C582524 | vesatolimod |
| D000069547 | Cobicistat |
| D065819 | Voriconazole |
| D017828 | Rifabutin |
| ID | Term |
|---|---|
| D002219 | Carbamates |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
| D013844 | Thiazoles |
| D013457 | Sulfur Compounds |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D014230 | Triazoles |
| D012294 | Rifamycins |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D047029 | Lactams, Macrocyclic |
| D047028 | Macrocyclic Compounds |
| D011083 | Polycyclic Compounds |
Not provided
Not provided
| Between 18 and 65 years |
|
| >=65 years |
|
|
|
|
|
|
| Geometric Least-squares Mean Ratio |
| 137 |
| 2-Sided |
| 90 |
| 99.5 |
| 189 |
Parametric (normal theory) mixed-effects ANOVA model was fitted to the natural log-transformed values of the PK parameter under evaluation. |
| Other |
Participants received VOR 200 mg twice daily on Days 2 to 6, and a single dose of VES 2 mg in the morning on Day 3 in Period 3.
| OG003 | Cohort 2: Vesatolimod 6 mg | Participants received a single dose of VES 6 mg on Day 1 in Period 1. |
| OG004 | Cohort 2: Vesatolimod 6 mg + Rifabutin 300 mg | Participants received RFB 300 mg once daily on Days 1 to 9 along with a single dose of VES 6 mg on Day 6 in Period 2. |
|
|
|
| OG003 |
| Cohort 2: Vesatolimod 6 mg |
Participants received a single dose of VES 6 mg on Day 1 in Period 1. |
| OG004 | Cohort 2: Vesatolimod 6 mg + Rifabutin 300 mg | Participants received RFB 300 mg once daily on Days 1 to 9 along with a single dose of VES 6 mg on Day 6 in Period 2. |
|
|
|
Participants received VOR 200 mg twice daily on Days 2 to 6, and a single dose of VES 2 mg in the morning on Day 3 in Period 3. |
| OG003 | Cohort 2: Vesatolimod 6 mg | Participants received a single dose of VES 6 mg on Day 1 in Period 1. |
| OG004 | Cohort 2: Vesatolimod 6 mg + Rifabutin 300 mg | Participants received RFB 300 mg once daily on Days 1 to 9 along with a single dose of VES 6 mg on Day 6 in Period 2. |
|
|
| OG003 |
| Cohort 2: Vesatolimod 6 mg |
Participants received a single dose of VES 6 mg on Day 1 in Period 1. |
| OG004 | Cohort 2: Vesatolimod 6 mg + Rifabutin 300 mg | Participants received RFB 300 mg once daily on Days 1 to 9 along with a single dose of VES 6 mg on Day 6 in Period 2. |
|
|
|
| OG003 | Cohort 2: Vesatolimod 6 mg | Participants received a single dose of VES 6 mg on Day 1 in Period 1. |
| OG004 | Cohort 2: Vesatolimod 6 mg + Rifabutin 300 mg | Participants received RFB 300 mg once daily on Days 1 to 9 along with a single dose of VES 6 mg on Day 6 in Period 2. |
|
|
| OG003 | Cohort 2: Vesatolimod 6 mg | Participants received a single dose of VES 6 mg on Day 1 in Period 1. |
| OG004 | Cohort 2: Vesatolimod 6 mg + Rifabutin 300 mg | Participants received RFB 300 mg once daily on Days 1 to 9 along with a single dose of VES 6 mg on Day 6 in Period 2. |
|
|
Participants received VOR 200 mg twice daily on Days 2 to 6, and a single dose of VES 2 mg in the morning on Day 3 in Period 3. |
| OG003 | Cohort 2: Vesatolimod 6 mg | Participants received a single dose of VES 6 mg on Day 1 in Period 1. |
| OG004 | Cohort 2: Vesatolimod 6 mg + Rifabutin 300 mg | Participants received RFB 300 mg once daily on Days 1 to 9 along with a single dose of VES 6 mg on Day 6 in Period 2. |
|
|
| OG003 | Cohort 2: Vesatolimod 6 mg | Participants received a single dose of VES 6 mg on Day 1 in Period 1. |
| OG004 | Cohort 2: Vesatolimod 6 mg + Rifabutin 300 mg | Participants received RFB 300 mg once daily on Days 1 to 9 along with a single dose of VES 6 mg on Day 6 in Period 2. |
|
|
|
| OG003 | Cohort 2: Vesatolimod 6 mg | Participants received a single dose of VES 6 mg on Day 1 in Period 1. |
| OG004 | Cohort 2: Vesatolimod 6 mg + Rifabutin 300 mg | Participants received RFB 300 mg once daily on Days 1 to 9 along with a single dose of VES 6 mg on Day 6 in Period 2. |
|
|
| OG003 | Cohort 2: Vesatolimod 6 mg | Participants received a single dose of VES 6 mg on Day 1 in Period 1. |
| OG004 | Cohort 2: Vesatolimod 6 mg + Rifabutin 300 mg | Participants received RFB 300 mg once daily on Days 1 to 9 along with a single dose of VES 6 mg on Day 6 in Period 2. |
|
|
Participants received COBI 150 mg once along with a single dose of VES 2 mg on Day 2 in Period 2. |
| OG003 | Cohort 1: Voriconazole 400 mg | Participants received a loading dose of VOR 400 mg twice daily on Day 1 in Period 3. |
| OG004 | Cohort 1: Voriconazole 200 mg | Participants received VOR 200 mg twice daily on Days 2 to 6 in Period 3. |
| OG005 | Cohort 1: Vesatolimod 2 mg + Voriconazole 200 mg | Participants received VOR 200 mg twice along with a single dose of VES 2 mg on Day 3 in Period 3. |
| OG006 | Cohort 2: Vesatolimod 6 mg | Participants received a single dose of VES 6 mg on Day 1 in Period 1. |
| OG007 | Cohort 2: Rifabutin 300 mg | Participants received RFB 300 mg once daily on Days 1 to 9 in Period 2. |
| OG008 | Cohort 2: Vesatolimod 6 mg + Rifabutin 300 mg | Participants received RFB 300 mg once along with a single dose of VES 6 mg on Day 6 in Period 2. |
|
|
Participants received a loading dose of VOR 400 mg twice daily on Day 1 in Period 3. |
| OG004 | Cohort 1: Voriconazole 200 mg | Participants received VOR 200 mg twice daily on Days 2 to 6 in Period 3. |
| OG005 | Vesatolimod 2 mg + Voriconazole 200 mg | Participants received VOR 200 mg twice along with a single dose of VES 2 mg on Day 3 in Period 3. |
| OG006 | Cohort 2: Vesatolimod 6 mg | Participants received a single dose of VES 6 mg on Day 1 in Period 1. |
| OG007 | Cohort 2: Rifabutin 300 mg | Participants received RFB 300 mg once daily on Days 1 to 9 in Period 2. |
| OG008 | Vesatolimod 6 mg + Rifabutin 300 mg | Participants received RFB 300 mg once along with a single dose of VES 6 mg on Day 6 in Period 2. |
|
|